-

SHAREHOLDER ALERT: Robbins LLP Reminds Investors of Class Action on Behalf of Tencent Music Entertainment Group (TME) Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Tencent Music Entertainment Group (NYSE: TME) securities between March 22, 2021 and March 29, 2021, for violations of the Securities Exchange Act of 1934.

If you own shares of Tencent Music Entertainment Group and suffered a loss, click here.

Tencent Music Entertainment Group (TME) Shareholders Harmed When Goldman Sachs Group and Morgan Stanley Sold Shares

According to the complaint, Goldman Sachs Group Inc. and Morgan Stanley sold Tencent Music shares while in possession of material non-public information. Specifically, Goldman Sachs and Morgan Stanley knew Archegos Capital Management would need to fully liquidate its position in Tencent Music based on margin call pressures. Goldman Sachs Group and Morgan Stanley sold billions worth of Tencent securities with this knowledge, sending Tencent stock into a tailspin and avoiding billions in losses. When the market learned the truth, investors suffered damages.

If you purchased shares of Tencent Music Entertainment Group (TME) between March 22, 2021 and March 29, 2021, you have until December 27, 2021, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Tencent Music Entertainment Group settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

MVST Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Microvast Holdings, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Microvast Holdings, Inc. (NASDAQ: MVST) securities between April 1, 2025 and March 16, 2026. Microvast purports to design, develop, and manufacture “advanced specialized battery technologies”, primarily for use in electric commercial vehicles and energy storage systems (“ESS”). For more information, submit a form, email attorney Aaron Dumas, J...

Robbins LLP Urges ZoomInfo Technologies Inc. Stockholders to Contact the Firm for Information About the Class Action Against GTM  

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ZoomInfo Technologies Inc. (NASDAQ: GTM) securities between November 3, 2025 and May 11, 2026. ZoomInfo Technologies Inc., together with its subsidiaries, provides go-to-market intelligence and engagement platform for sales, marketing, operations, and recruiting professionals in the United States and internationally.For more information, submit...

Erasca, Inc. Class Action Reminder - Robbins LLP Encourages ERAS Stockholders to Contact the Firm for Information About Their Rights  

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025 and April 26, 2026. Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...
Back to Newsroom